Comprehensive Session Report

This report is built entirely from your data — de-identified, organised, and yours to keep or share.

As you continue depositing health information over time, these reports compound. Sections expand, patterns emerge, and the clinical picture becomes richer with each session. At the front of every report is a concise summary written specifically for health professionals — designed to orient your GP or specialist to the full record quickly.

The value of SOPHIA grows the more you use it: all your health information, de-identified, in one place, shareable with health professionals, family, or anyone you choose. Over time, you learn more about your own health — and when you do work with a health professional, that collaboration starts from a position of knowledge rather than guesswork.

For support or to give feedback, contact Hartmut on hart@hartgood.com or phone 0439 547 788 (international +61 439 547 788).

What I feel and report, tracked over time.

Left hip pain (since December 2024)

Left hip, deep, ilial area. Anatomically anchored to imaging on file: the December 2024 X-ray shows very minimal joint space narrowing, and the January 2025 MRI (reported by the radiologist) describes an anterosuperior acetabular labral tear with a small paralabral cyst (~10 × 2 mm), an oedematous ligamentum teres with mild laxity suggestive of partial tear, and focal subchondral oedema of the peripheral anterior acetabulum that may represent a sequel of prior trauma. Articular cartilage was reported as normal and tendons intact. Imaging findings are described in Appendix C.

Two qualitatively distinct symptom patterns are now sitting alongside each other:

Pattern 1 — walking-onset deep pain.

Reliably emerges around the 15–20 minute mark of walking — a pattern I recognise as having been with me for around the last 18 months. It is reliably eased by stopping, by mid-walk exercise (push-ups performed with the back held straight; standing quadriceps stretch alternated between legs), and by a postural-change strategy from the exercise physiologist (standing tall, leaning forward slightly while continuing to walk).

Pattern 2 — NEW intermittent rotational catching (17 June 2026).

An acute sharp pain on unusual or rotational movements — for example, rotating the body up and down — that resolves immediately, feeling as though something has shifted, clicked, or caught and then released. Catching/clicking phenomena can arise from labral and ligamentum teres structures already documented on the January 2025 MRI; worth flagging directly with the orthopaedic and physiotherapy team.

Trajectory timeline

• 2024-12-09X-ray: very minimal joint space narrowing
• 2025-01-08MRI: anterosuperior labral tear with paralabral cyst; partial ligamentum teres tear with mild laxity
• 2026-05-23Worst day in the cumulative record
• 2026-05-24, 27, 28Relatively pain-free / minimal
• 2026-05-29Daytime hip pain on and off while walking; well-managed by mid-walk strategies; pain-free by evening
• 2026-05-30 → 06-01Recurring flare pattern with daytime discomfort
• 2026-06-01 & 06-02 overnightTerrible sleep from pain; PRN paracetamol + ibuprofen taken
• 2026-06-02 & 06-03'On the other side again' — hardly any pain
• 2026-06-03 → 06-09A full week of very little overnight pain
• 2026-06-09Good night; morning walk: pain came on at the 15–20 minute mark, eased by stopping, mid-walk exercise, and postural change
• 2026-06-15 (approx)Three walks during a heavy people-focused work day; walking-onset pain at the familiar 15–20 minute mark; marked fatigue ('shattered') by 3:30–4 pm
• 2026-06-17Rainy day, one walk only; energy sustained through to bedtime. Overnight pain remains absent — 'mostly an absence of pain, which is fantastic, particularly at night while sleeping, so that seems to have resolved'. NEW symptom quality: intermittent rotational catching with brief acute sharp pain

Current status: overnight pain has been sustainedly quiet and I frame this aspect as resolved. The walking-onset deep pain at 15–20 minutes remains the familiar pattern, well-managed by a layered set of easing strategies. The new rotational catching is a fresh symptom quality worth flagging with the orthopaedic and physiotherapy team. Suggested follow-up: orthopaedic review (referral on file with an orthopaedic surgeon, Hobart) and ongoing physiotherapy.

Nocturia (surfaced May 2026)

Waking overnight to urinate, approximately every couple of hours. Voids are NOT small — previously quantified at ~1.5 L total nocturnal output across multiple voids, on most nights or every other night. On 3 June 2026 I noticed nocturia persisted overnight and attributed part of the pattern to a couple of cups of (non-caffeinated) herbal tea earlier in the evening — a fluid-volume contribution rather than a stimulant one. That evening fluid-timing variable is useful to track but does not displace the broader picture: the ~1.5 L nocturnal output baseline is not explained by a couple of evening cups alone.

The substantial overnight output suggests daytime fluid being mobilised when supine. The differential is multifactorial — prostatic, cardiovascular (nocturnal natriuresis from third spacing), thyroid-related fluid handling, sleep architecture — and I have independently raised the question of where the accumulated daytime fluid is being held, linking it to a perceived abdominal bulge tracked in Section 4.

Current status: the pattern continues. Evening fluid-timing is a sensible self-experiment variable; the structured workup with the treating team remains the clinically meaningful pathway given the ~1.5 L nocturnal output baseline.

Recurrent diplopia (May 2026 record)

Transient double vision — three discrete episodes captured in the cumulative record. The exact episode dates are flagged for verification. This sits alongside the blood-pressure lability described below and the lipid profile on labs; the combination is the reason a neuro-vascular workup is on the suggested investigations list. The OPTOS widefield fundus and REVO FC widefield OCT imaging captured at the optometrist on 25 March 2026 (left eye) are on file but were deposited without an accompanying written interpretation — obtaining the optometrist's written read is the most immediate step. Imaging findings are described in Appendix C.

Current status: not reported in recent sessions. Episodes documented; investigative pathway outstanding.

Blood pressure lability (May 2026 record)

Variable systolic readings captured: 169/90 and 180/91, with a post-walk reading of 134/89. Suggests a sympathetic / pain-driven amplification on an isolated systolic background. 24-hour ambulatory monitoring would clarify the pattern.

Current status: not reported in recent sessions. Investigative pathway outstanding.

Risks — what genetics and measurements suggest as relative and absolute risk, not destiny.

Family history. No family history items deposited yet. Once added, each item will sit here as relation, condition, age at onset, and outcome — useful context for relative risk, never destiny.

Biometrics

Family history and biometric trajectories indicate relative and absolute risk — they shape probabilities, not destiny.

The Nine Health Investments frame this as agency over the modifiable terrain. Read more on the Nine Health Investments framework.

Things I don't feel but should heed — considerations from labs, imaging, and objective data.

These are clinical considerations drawn from labs, imaging, and objective measurements. Many carry no day-to-day sensation. The hip structural findings and the diplopia picture are not repeated here — they sit in full under Main Complaints above.

Thyroid trajectory — discuss soon.

Sustained TSH elevation across the cumulative record, with new March 2026 data adding important detail: TSH 9.5 mU/L (NWP reference 0.3–5.0), FT4 9.3 pmol/L (just below the 10.0–20.0 reference), FT3 4.0 pmol/L (reference 2.3–5.7), and reverse T3 320 pmol/L (within reference 140–540). TPO antibodies rising 540 → 620 IU/mL across 2023–2024. The TSH series across labs/references: 7.29 (2019, ref 0.40–4.00), 19/15/13/18 (2022–2024, ref 0.50–4.00), 9.5/9.9/9.5 at NWP (Jul 2021, Sep 2023, Mar 2026, ref 0.3–5.0). FT4 series at NWP: 10.6 → 8.7 → 9.3 — a downward trajectory now sitting just below the lower reference. Suggested follow-up: endocrinology review of the full peripheral-conversion picture (TSH, FT4, FT3, rT3, TPO Ab) with the trajectory in hand. No current pharmacological therapy on file. Thyroid status and lipid metabolism can be related — the lipid profile sits naturally in the same conversation.

Lipid profile — worth discussing.

TC 6.8, LDL 4.5, TG 3.0, HDL 0.9 mmol/L (2024). No current pharmacological therapy on file. Conversation with GP useful; sits biochemically alongside thyroid status above.

Renal function — for awareness.

eGFR 71 mL/min/1.73m² (2026, below the >89 reference) and urine ACR 2.6 mg/mmol (at upper limit of reference). Clinically relevant given BP lability and PRN NSAID use; an analgesic-choice conversation with the GP is sensible.

Cardiovascular / neuro-vascular cluster — discuss soon.

Three transient diplopia episodes against BP readings to 180/91 and an elevated lipid profile. Suggested follow-up: neuro-vascular workup for the diplopia and 24-hour ambulatory BP monitoring to characterise the lability pattern.

See the Laboratory Results spreadsheet for the full longitudinal picture. The spreadsheet shows patterns, trends, precautions, and successes in one window — pink for values above range, blue for below, amber for alignment-uncertain. There is nothing currently in existence, either medically or otherwise, that can replace the side-by-side view across time.

What is new / changed / stable in the longitudinal picture.

This session adds the missing peripheral-conversion piece for the thyroid: FT3 4.0 pmol/L and reverse T3 320 pmol/L (both 27 March 2026), against FT4 9.3 pmol/L and TSH 9.5 mU/L from the same draw. The conversion ratios can now be examined in context. Stable picture across the wider record: haematology shows a seven-year gradual Hb decline (162 → 142 g/L, 2019–2026) with an iron redistribution pattern (iron 14, transferrin at lower limit, ferritin preserved at 147); fasting glucose 4.7 and fasting insulin 7 sit within range — a limited snapshot from which glycaemic and insulin-resistance status cannot be characterised or excluded, and fuller longitudinal assessment is the meaningful pathway; hs-CRP 0.8 and HbA1c 5.2%; 25-OH-D 51 nmol/L just above floor; bilirubin returned to 19 (peaked 29 in 2022).

Minor perceived issues — sleep, mood, fatigue, emotions, relationships, stress.

Sleep

Consistent sleep/wake schedule — 9 June 2026

A regular bedtime around 8:00–8:30 pm and rise time around 5:30–6:00 am — a stable, deliberate routine. The recent week of quiet nights (very little overnight hip pain) sits alongside this consistent rhythm. Sleep regularity is a known modulator of circadian rhythm and may be a contextual factor in the recent quietening of overnight hip pain.

Fatigue

End-of-day energy note — 29 May 2026

Energy levels 'obviously okay' as I was still working at 7:30 pm, with the self-observation 'I'll be glad to finish pretty soon' — adequate energy for task completion with awareness of approaching depletion. Pain-free at end of day noted as a positive marker.

Daytime energy baseline — 9 June 2026

Energy levels generally pretty good throughout the day.

Activity- and people-load related afternoon fatigue — 15 June 2026 (approx)

On a day with three walks alongside heavy people-focused work, marked fatigue — 'absolutely shattered' — set in by 3:30–4 pm and persisted for the next few hours. The following day (rainy, one walk only, lighter load) showed sustained energy right through to bedtime — a clear self-noted contrast. I am identifying activity load + interpersonal demand as candidate drivers of the afternoon fatigue.

Other

Abdominal distension / bulge — 29 May 2026

A notable abdominal bulge is visible when the abdomen is relaxed and less prominent when consciously drawn in. Two side-profile photos deposited this session (relaxed and held-in views). I link the bulge to the broader question of where daytime fluid is being accumulated, given the nocturia pattern, and have asked for an approximate visual estimation of visceral fat. Caveat: photographic visceral-fat estimation is not a quantitative method — waist circumference, waist-to-height ratio, and where available DEXA or bioimpedance carry the actual measurable signal.

The Nine Health Investments frame sleep as a daily reset — the regular rhythm visible here is a meaningful protective factor. Read more on Rest & Sleep.

Aerobic capacity, strength, stamina, endurance — tracked over time.

Aerobic

Twice-daily walking pattern (since May 2026, ongoing — stable). Sustained through the May 2026 hip flare-recovery cycle. Outdoor walking also supports natural light exposure.

29 May 2026 — stable

~30-minute walk at 7:30 am after an early coffee with a friend at 7 am as part of a 'new normal' routine; walk maintained despite a rough night with hip pain.

29 May 2026 — stable

Two walks completed (morning and afternoon) despite a workday dominated by sustained computer work and intermittent housework. Afternoon walk specifically taken as a counterbalance to heavy computer load.

17 June 2026 — shifted

Recent activity pattern has shifted: much less gym work (little elliptical walking, little bike riding), focus mainly on walking. Day before yesterday: three walks completed during a heavy work day. Yesterday/today: rainy weather limited to one walk. Walking-onset hip pain at 15–20 minutes consistent across these walks and reliably eased by movement strategies.

Strength

Gym attendance (since May 2026 — stable, but reduced in mid-June). Maintained at age 72 alongside an active hip presentation; recent pattern shows reduced gym attendance with walking emphasised.

Flexibility

Physiotherapy programmes (since May 2026 — stable). Two structured prescriptions on file and being followed (with the physiotherapist, NW Tasmania).

Self-directed mid-walk strategies (29 May 2026 — emerging). Push-ups performed with the back held straight, and a standing quadriceps stretch (holding foot behind while balancing on one leg), alternated between legs. Reported as helping to minimise intra-walk discomfort.

Postural-change strategy from the exercise physiologist (9 June 2026 — stable). Standing tall, leaning forward slightly while continuing to walk. Reported as reliably easing the walking-onset hip pain at the 15–20 minute mark. Used alongside the self-directed mid-walk strategies above.

Movement & Strength is one of the Nine Health Investments and is particularly important with ageing — the sustained walking, the strength work, the physiotherapy adherence, and the self-developed easing strategies are a layered, meaningful set. Read more on Movement & Strength.

Diet, supplements, medications, recreational substances — and how they interact.

(a) Diet

The cumulative record carries two dietary observations. A single-day snapshot on 29 May 2026: small muffin and coffee at breakfast; two eggs with leftovers from the previous night's dinner later that morning; some fruit and a can of sardines across the day; bean ragu with plenty of vegetables, tomato, and avocado for dinner; dried fruit and a couple of biscuits as desserts/extras. Mixed-quality day: protein anchors present (eggs, sardines, bean ragu), vegetables substantial at dinner, avocado adding monounsaturated fat; daytime carbohydrate load includes added sugars from muffin, dried fruit, biscuits; caffeine one coffee at breakfast. And a 2 June 2026 fluid-timing observation: a couple of cups of (non-caffeinated) herbal tea earlier in the evening — the fluid-volume contribution being the relevant variable, captured as part of self-experimentation around the nocturia pattern.

Approximate only, against Australian Nutrient Reference Values (NHMRC). Each nutrient's intake is ESTIMATED by inferring approximate portion sizes from the dietary description (the same approach mainstream photo-based nutrition tools use), and each % RDI is expressed as a range — the range itself signals the estimation uncertainty. Portion weights are estimated from the dietary description, NOT weighed. This is a transparent estimate to give a sense of scale; it is not a measured value and not a clinical assessment of dietary adequacy. Based on a single-day snapshot — not a generalised pattern.

(b) Supplements

% RDI against Australian NRVs (NHMRC). Shown as "—" where the supplement label amount has not been confirmed — this calculation is pending confirmation of label details.

(c) Medications

(d) Recreational substances

No alcohol entries on file. Caffeine: one coffee at breakfast captured in the 29 May snapshot. No other recreational substances on file.

(e) Interactions — worth awareness

• Curcumin/turmeric daily + PRN ibuprofen. Both have antiplatelet-style effects; the combined effect over flare days is worth discussion with the prescribing practitioner.
• Iodine + autoimmune-pattern thyroid trajectory. Iodine in the context of rising TPO antibodies and sustained TSH elevation is a sensitive area for ongoing discussion with the prescribing practitioner.
• PRN NSAID + reduced eGFR (71) and ACR 2.6. Worth an analgesic-choice conversation with the GP given the renal picture.
• Hemp seed oil / turmeric / curcumin overlap. Cumulative curcumin exposure from multiple sources is worth being aware of for the same antiplatelet reason as above.

Sustenance is one of the Nine Health Investments — the dietary, supplement, and medication picture sits inside it. Read more on Sustenance.

Living-context exposures — air, water, soil, dust, food, occupational, and hair-mineral analysis.

Hair-mineral analysis is read here strictly as an exposure marker. Only elements at or above four times the population average are interpreted in this narrative; everything below that threshold appears in the spreadsheet for completeness but is not commented on. Hair indicates exposure and the extent of exposure — it does not measure how much of a substance is stored in body tissues, how much is being excreted, or how the body is handling it internally. Hair, urine, and blood are complementary windows on different things, never substitutes for one another.

Hair-mineral analysis (ToxTest, 18 April 2026)

Source investigation

Mercury exposure marker sustained at ~7.5× population average across serial samples 2020–2026 — a chronic exposure pattern. Likely sources to revisit with the treating team include dental amalgam history, fish consumption frequency and species (large predatory species carry more), and any occupational or environmental exposure. Hair indicates exposure, not body burden.

No water, soil, dust, food, or occupational-exposure testing on file yet. These are available and can be deposited here.

Stuff to Avoid in the Nine Health Investments framework speaks to the environmental side of the terrain — where reasonable, reducing ongoing exposure is the agency lever. Read more on Stuff to Avoid.

When practised regularly or daily, this provides contentment, meaning, a complete reset, and enhanced agency to participate in life — and, most importantly, it is independent of external circumstances.

Meditation

Daily one-hour morning meditation — first surfaced 3 June 2026

Provides significant clarity, understanding, and goodness throughout the day. Reported as a pre-existing routine newly disclosed in the cumulative record.

Continuation — 9 June 2026

'Still meditating for an hour every morning' — established daily practice ongoing.

Know Thy Self is one of the Nine Health Investments — a daily meditation practice independent of circumstances is a significant lever. Read more on Know Thy Self.

What I am learning, researching, deciding, and hypothesising about my own health — an accumulating, dated record.

Choices & decisions

29 May 2026 — GP appointment cancelled

I cancelled the GP appointment because the report was not yet ready to hand over. I am comfortable with the deferral.

17 June 2026 — Shifted activity mode

Much less gym work (elliptical, bike) currently; focus mainly on walking.

Insights & hypotheses

• 29 May 2026 — Mid-walk movement strategies hypothesis. Push-ups with back straight and standing quadriceps stretch appear to ease intra-walk hip discomfort — strategies I am actively self-testing.
• 29 May 2026 — Where is the fluid being held? Linking the substantial overnight urinary output to a perceived abdominal bulge — querying where the accumulated daytime fluid is being stored.
• 2 June 2026 — Recurring bad-night / better-day rhythm. A repeating pattern of overnight pain peaks followed by a markedly better day — the rhythm itself is the finding worth characterising.
• 3 June 2026 — Evening fluid timing. A couple of cups of herbal tea earlier in the evening as a fluid-volume contribution to overnight nocturia frequency.
• 9 June 2026 — Postural-change strategy. The exercise physiologist's posture suggestion (stand tall, lean forward slightly while walking) reliably eases the walking-onset hip pain at the 15–20 minute mark.
• 15–17 June 2026 — Activity + people-load as fatigue drivers. Side-by-side comparison of a heavy-load three-walk day (shattered by 3:30–4 pm) and a rainy one-walk lighter-load day (energy sustained to bedtime) — identifying combined activity and interpersonal demand as candidate drivers of afternoon fatigue.
• 17 June 2026 — New rotational catching sensation. An acute sharp pain on rotational movements (rotating the body up and down) that resolves immediately, feeling as though something has shifted or caught — a new symptom quality I will raise with the orthopaedic and physiotherapy team.
• 17 June 2026 — Overnight pain framed as resolved. 'Mostly an absence of pain, which is fantastic, particularly at night while sleeping, so that seems to have resolved' — my own framing of the sustainedly quiet overnight period.

Learning, Thinking & Behaviour is one of the Nine Health Investments — the accumulating dated record of one's own thinking is its own form of agency. Read more on Learning, Thinking & Behaviour.

Plain-language definitions of clinical and technical terms used in this report.

Absolute risk

The actual chance, expressed as a number, of a particular event happening over a defined time (e.g. "5 in 100 over 10 years").

ACR (albumin-to-creatinine ratio)

A urine test that measures protein leakage from the kidney; a sensitive early marker of kidney stress.

Acetabulum

The cup-shaped socket of the pelvis that holds the head of the femur.

Albumin

The main protein in blood, made by the liver; carries hormones, nutrients, and drugs.

Anterosuperior

Toward the front and upper part of a structure.

Antiplatelet effect

Reduction in the blood's tendency to clot via platelet inhibition.

Bicarbonate

A blood buffer that helps regulate pH.

BMI (Body Mass Index)

Weight in kilograms divided by height in metres squared; a screening measure, not a diagnosis.

Diplopia

Double vision.

eGFR (estimated glomerular filtration rate)

An estimate of how well the kidneys filter blood, expressed in mL/min/1.73m².

Endocrinology

The medical speciality concerned with hormones and the glands that produce them.

Ferritin

The storage form of iron; a marker of iron reserves.

Free T3 (FT3)

The active circulating thyroid hormone available to tissues.

Free T4 (FT4)

The main circulating thyroid hormone, converted to T3 peripherally.

GGT

Gamma-glutamyl transferase, a liver enzyme.

HbA1c

Glycated haemoglobin; reflects average blood glucose over the previous ~3 months.

HDL

High-density lipoprotein cholesterol; traditionally considered protective.

Hs-CRP

High-sensitivity C-reactive protein; a marker of low-grade inflammation.

Insulin resistance

Reduced cellular response to insulin; cannot be characterised from a single fasting glucose and fasting insulin alone.

LDL

Low-density lipoprotein cholesterol.

Labrum (acetabular)

A ring of cartilage around the rim of the hip socket that deepens the joint.

Ligamentum teres

A ligament from the femoral head to the acetabulum that contributes to hip stability and blood supply.

NSAID

Non-steroidal anti-inflammatory drug, such as ibuprofen.

Nocturia

Waking from sleep to urinate.

Nocturnal natriuresis

Increased overnight sodium and water excretion, often related to daytime fluid accumulation being mobilised supine.

Nocturnal polyuria

Substantial total nocturnal urine output (commonly >1/3 of 24-hour output overnight).

OCT (optical coherence tomography)

High-resolution cross-sectional imaging of the retinal layers.

OPTOS

A widefield retinal imaging device used by optometrists.

Paralabral cyst

A fluid-filled cyst adjacent to a torn labrum, often associated with the tear.

Peripheral conversion (thyroid)

The conversion of FT4 to FT3 (active) and reverse T3 (inactive) in body tissues.

PRN

"As needed" (from Latin pro re nata).

Reference range

The laboratory's expected value range for a healthy reference population.

Relative risk

How much a risk factor multiplies the chance of an event compared with someone without that factor (e.g. "1.5× the risk").

Reverse T3 (rT3)

An inactive metabolite of FT4; elevated rT3 with low FT3 can indicate altered peripheral conversion.

Subchondral oedema

Fluid signal in the bone just below the joint cartilage, often related to stress or injury.

TIBC

Total iron-binding capacity; reflects transferrin's capacity to carry iron.

Third spacing

Fluid accumulating in interstitial tissues rather than circulating in the bloodstream.

TPO antibodies (thyroid peroxidase antibodies)

Autoantibodies against a thyroid enzyme; a marker of autoimmune thyroid involvement.

Transferrin

The blood protein that carries iron.

Transferrin saturation

The percentage of transferrin currently carrying iron.

Triglycerides

Blood fats; elevated triglycerides are part of cardiometabolic risk.

TSH (thyroid-stimulating hormone)

Pituitary hormone that signals the thyroid; elevated TSH typically indicates the thyroid is being driven harder to produce hormone.

Widefield fundus imaging

Wide-angle photography of the back of the eye including the peripheral retina.

Sources the client has supplied or referenced — added as the record grows.

Imaging, photos, and visual records deposited across sessions.

Retinal fundus (OPTOS widefield, left eye) — 25 March 2026

Two widefield fundus images of the left eye captured at the optometrist on the OPTOS P200T OptomapPlus: an autofluorescence (grayscale) image and a red-green pseudocolor composite. Optic disc, retinal vasculature, and macula visible. No accompanying optometrist interpretation was deposited. Interpretation framework: OPTOS widefield fundus is a screening modality for peripheral retinal involvement, vascular changes (hypertensive or diabetic retinopathy), pigmentary changes, and macular health. In the present clinical context — three transient diplopia episodes, BP lability to 180/91, an elevated lipid profile, and a sustained mercury exposure marker — retinal vascular assessment is clinically relevant. Without the actual ophthalmology read, specific findings cannot be characterised; obtaining the optometrist's written interpretation is the most useful next step.

Retinal OCT (REVO FC OPTOPOL widefield, left eye 12 × 12 mm) — 25 March 2026

Widefield optical coherence tomography of the left eye, single scan at 08:48:20 (quality index 8). Map types present: retina thickness, retina sectors value, RPE deformation, retina significance, NFL+GCL+IPL thickness and significance, NFL thickness and significance, plus horizontal and vertical B-scans. Metadata and map-type labels captured; numerical sector values not extracted as machine-readable data into this deposit. No optometrist interpretation accompanied the file. Interpretation framework: widefield 12 × 12 mm OCT extends beyond the standard macular cube and assesses peripheral retinal layers, the retinal nerve fibre layer (NFL), the ganglion cell + inner plexiform layer (GCL+IPL), the retinal pigment epithelium (RPE), and overall retinal thickness with significance maps comparing to normative percentiles. Clinically this modality screens for glaucomatous nerve fibre loss, macular pathology, RPE changes, and vascular sequelae. In the present clinical context — age 72, recurrent transient diplopia, BP lability, elevated lipid profile, and a sustained mercury exposure marker — NFL/GCL integrity and RPE status are particularly worth knowing. Obtaining the optometrist's written interpretation and, where indicated, an ophthalmology referral is the most useful next step.

MRI left hip — key slices (8 January 2025)

Three key image slices marked with green arrows / circles by the radiologist, indicating the area of structural involvement around the superior aspect of the left hip joint. Sagittal PD TSE fat-saturated view shows the femoral head within the acetabulum. Findings: three key slices selected from the 8-sequence MRI series, marked to highlight the area of structural involvement (anterosuperior labrum and adjacent acetabular rim).

Radiologist report — page 1 (cover, 8 January 2025)

MRI report cover page. Non-contrast MRI of the left hip. Clinical indication: left hip pain ~4 months, worsening; runner; unable to lift left leg due to pain. Initial findings: congruent hip joints with normal femoral head–neck junction morphology bilaterally; no acetabular over-coverage; no joint effusion or synovitis on either side.

Radiologist report — page 2 (conclusion, 8 January 2025)

Radiology report signed by the reporting radiologist. Conclusion: (1) Anterosuperior acetabular labral tear with small associated paralabral cyst (~10 × 2 mm). (2) Oedematous ligamentum teres with loss of normal architecture and mild laxity, suggestive of injury / at least partial tear. (3) Focal subchondral oedema of the peripheral anterior acetabulum of uncertain acuity / chronicity; may represent sequel of prior trauma. Articular cartilage normal; tendons intact; no tendinosis; ischiofemoral space normal; sciatic nerve normal.

MRI left hip — full image series (8 January 2025)

Full MRI image series: 8 sequences containing multiple slices, plus 3 key slices identified by the radiologist. Imaging sequences acquired: T1 Weighted Coronal (#1); T1 TIRM Coronal (#2); HASTE Localizer (#3); T2 TSE Axial (#4); PD TSE FS Axial (#5); Coronal PD TSE FS (#6); Coronal PD TSE non-fat-suppressed (#7); PD FS Sagittal (#8); Oblique Axial PD TSE (#9). Three slices key-marked by the radiologist correspond to the area of structural involvement.

Image PII guard: source documents carry patient identifiers in pixel form, so findings are rendered as text only and the raw images are not embedded in this report.

Complete session transcripts, most recent first — so you can review exactly what was said.

Session — 17 June 2026, 08:29 pm

Deposit 1 — pathology image upload (Thyroid Function Test, North West Pathology, collected 27 March 2026, reported 27 March 2026 17:18, specimen type serum):

• TSH 9.5 mU/L (22 July 2021) — reference 0.3–5.0 — H
• TSH 9.9 mU/L (22 September 2023) — reference 0.3–5.0 — H
• TSH 9.5 mU/L (27 March 2026) — reference 0.3–5.0 — H
• Free T3 4.0 pmol/L (27 March 2026) — reference 2.3–5.7
• Free T4 10.6 pmol/L (22 July 2021) — reference 10.0–20.0
• Free T4 8.7 pmol/L (22 September 2023) — reference 10.0–20.0 — L
• Free T4 9.3 pmol/L (27 March 2026) — reference 10.0–20.0 — L

Comments: Tests Completed — TSHFT4, TSHFT4FT3, TFT. Tests Pending — Reverse T3.

Deposit 2 — pathology image upload (SE-Reverse T3, North West Pathology, collected 27 March 2026, reported 31 March 2026 16:18, specimen type serum):

• Reverse T3 320 pmol/L (27 March 2026) — reference 140–540

Comments: Tests Completed — TSHFT4, TSHFT4FT3, TFT, Reverse T3.

Deposit 3 — report request: "Generate the structured report based on everything I've shared. Include the full raw transcript. Include the Investigative Pathways section."

Note on the Investigative Pathways section: the current report template merges what used to be a separate Investigative Pathways section into the Clinical Summary for Treating Practitioner (under "Clinical considerations & suggested investigations") and into Section 3 (per consideration, with suggested investigations/reviews). Both have been completed accordingly in this report.

Earlier session transcripts are not reproduced verbatim in this report; they are summarised in the dated entries throughout Sections 1–9. As the cumulative record grows, prior session transcripts deposited into SOPHIA will accumulate in this appendix, most recent first.